Company intelligence / Profile preview

BAROnova

San Jose, California, United States6sense.com ↗

Ownership: Private
Development stage: Phase 3

Overview

BAROnova developed the TransPyloric Shuttle® (TPS), a non-surgical medical device for weight loss in obese patients. The TPS system works by slowing gastric emptying to induce satiety and reduce caloric intake. Clinical trials demonstrated safety and effectiveness for weight reduction; the pivotal ENDObesity II study supported FDA approval in April 2019.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed prior to acquisition.

Beyond the preview

Go deeper on BAROnova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAROnova.

Explore the full profile